BIODISTRIBUTION STUDY OF 188Re-HEDP AS A RADIOPHARMACEUTICAL FOR BONE PAIN PALLIATION

  • Toni Tripunoski Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Domokos Mathe Frederic Joliot-Curie National Institute of Radiobiology and Radiohygiene, Dept. of Applied Radioisotopes, Budapest, Hungary
  • Lajos Balog Frederic Joliot-Curie National Institute of Radiobiology and Radiohygiene, Dept. of Applied Radioisotopes, Budapest, Hungary
  • Ana Ugrinska Department of Radioisotopes and Radiopharmaceuticals Production, University Institute of Positron Emission Tomography, Skopje, North Macedonia
  • Maja Chochevska Department of Radioisotopes and Radiopharmaceuticals Production, University Institute of Positron Emission Tomography, Skopje, North Macedonia
  • Sinisa Stojanoski Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Nikolina Bozinovska Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Nevena Manevska Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Anamarija Jankulovska Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Daniela Popgjorceva Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

Abstract

Bone seeking radiopharmaceuticals like Rhenium-188 hydroxy ethylidene diphosphonate (188Re-HEDP) are used for palliative treatment of bone metastases, and as target radionuclide therapy in patients with inoperable osteosarcoma in addition to the external radiation therapy. In this study was evaluated the preparation, quality control and biodistribution of 188Re-HEDP in mice to be determined the in vivo affinity to the target bone tissue and to the other non-target tissues and organs. 188Re-HEDP was prepared with radiochemical purity of 98.87%. Its biodistribution data showed high uptake and durability in the skeletal tissues without significant uptake in other tissues and organs. It means that 188Re-HEDP kit formulation and the prescribed conditions in our study allows obtaining a radiopharmaceutical with promising therapeutic efficiency in palliative treatment of primary bone tumors as well as secondary osseous metastatic lesions.


Keywords: bone pain palliation, radionuclide therapy, radiopharmaceuticals, Rhenium-188

References

1. Kunos CA, Capala J, Kohn EC, Ivy SP. Radiopharmaceuticals for persistent or recurrent uterine cervix cancer. Front Oncol (2019) 9:560. doi: 10.3389/fonc.2019.00560 - DOI - PMC - PubMed.
2.Kunos CA, Howells R, Chauhan A, Myint ZW, Bernard ME, El Khouli R, et al. Radiopharmaceutical validation for clinical use. Front Oncol (2021) 11:630827doi: 10.3389/fonc.2021.630827.
3.Lepareur, N.; Lacœuille, F.; Bouvry, C.; Hindré, F.; Garcion, E.; Chérel, M.; Noiret, N.; Garin, E.; Knapp, F.F.R. Rhenium-188 labeled radiopharmaceuticals: Current clinical applications in oncology and promising perspectives. Front. Med. 2019, 6, 132. [Google Scholar] [CrossRef] .
4.Lin WY, Hsieh JF, Lin CP, Hsieh BT, Ting G, Wang SJ, Knapp FF JR., 1999. Effect of reaction conditions on preparations of rhenium-188 hydroxy ethylidene diphosphonate complexes. Nucl Med Biol. 26(4):455-9. doi: 10.1016/s0969-8051(99)00007-4. PMID: 10382850.
5.Mani RS. Radiopharmaceuticals, Biodistribution studies-general aspects: Handbook of Nuclear Medicine Practice in Developing Countries. Viena: IAEA, 1991: 213-217.
6.Kleynhans J, Duatti A, Bolzati C. Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry. Molecules. 2023; 28(3):1487. https://doi.org/10.3390/molecules28031487.
7.Liepe K. 188Re-HEDP therapy in the therapy of painful bone metastases. World J Nucl Med. 2018 Jul-Sep;17(3):133-138. doi: 10.4103/wjnm.WJNM_85_17.
8.Pourhabib, Z., Ranjbar, H., Bahrami Samani, A., Azizkalantari, B. Preparation and biological evaluation of 186/188Re-HEDP as a new cocktail radiopharmaceutical for palliative treatment of osseous metastases in wild type rat. Iranian Journal of Nuclear Medicine, 2021; 29(1): 8-14.
9.Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clinic proceedings. 2008;83(9):1032-1045. doi: 10.4065/83.9.1032.
10. Deutsch E, Libson K, Vanderheyden J, Alan R, Maxon RH., 1986. The Chemistry of Rhenium and Techenetium as Related to the Use of Isotopes of these Elements in Therapeutic and Diagnostic Nuclear Medicine, Nucl. Med. Biol. 13(4): 465-477.
11. Tripunoski T. and Mathe D., Andocs G., Balogh L.,Polyak A., Ugrinska A., Chaudhari P.R., Janoki Gy.A., Gorgoski I., Vaskova O., 2006. Prediction of 188Re-HEDP tumor uptake based on 99mTc-MDP skeletal scintigraphy using spontaneous osteosarcoma bearing dogs as pathological animal model, Acta Morphologica,3(1):38-42
12. Hosain F, Spencer RP, Radiopharmaceuticals for Palliation of Metastatic Osseus Lesions: Biologic and Physical Background, Seminars in Nuclear Medicine, 1992; 22(2): 11-16.
13. Lewington VJ, Targeted radionuclide therapy for bone metastases, EJNM, 1993; 20:66-74.
14. Klain M. et all., Radioiodine therapy for papillary and follicular thyroid carcinoma, EJNM, 2002; 29(2): S479-S485.
15. Pakula RJ, Scott PJH. Applications of radiolabeled antibodies in neuroscience and neuro-oncology. J Labelled Comp Radiopharm. 2023 Jul;66(9):269-285. doi: 10.1002/jlcr.4049. Epub 2023 Jun 15. PMID: 37322805.
16. Nowotnik DP. Physico-Chemical Concepts in The Preparation of Technetium Radiopharmaceuticals: Textbook of Radiopharmacy. Cambridge: Gordon & Breach Science Publishers, 1994: 29-51.
17. Winter DE et all, Visualisation of the Stomach on Renium-186 HEDP Imaging After Therapy for Metastasized Prostate Carcinoma, Clin.Nuc.Med.,1999; 24(11):898-899.
18. Maxon RH et all, Re-188(Sn)HEDP for treatment of osseous metastases, JNM, 1998; 39(4): 659-663.
19. Hsieh BT et all., Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases, Nuclear medicine and Biology, 1999; 26(8):973-976.
20. Lin WJ et all., Rhenium-188 hydroxyethylidene diphosphonate: a new generator produced radiotherapeutic drug of potential value for the treatment of bone metastases, EJNM and Molecular Imaging, 1997; 24(6):590-595
21. Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010 Jul;40(4):220-41. doi: 10.1053/j.semnuclmed.2010.02.004. PMID: 20513446.
22. Lisic EC et all., Synthesis of a new bisphosphonic acid ligand (SEDP) and preparation of a 188Re-(Sn)SEDP bone seeking radiotracer, Nuclear medicine and Biology, 2001;28:419-424.
23. Schumichen C. et all, Binding of Technetium-99m to Plasma Proteins on the Distribution of Tc-99m Phosphate Agents, JNM, 1980; 21: 1080-1085.
Published
2023-12-27
How to Cite
TRIPUNOSKI, Toni et al. BIODISTRIBUTION STUDY OF 188Re-HEDP AS A RADIOPHARMACEUTICAL FOR BONE PAIN PALLIATION. Journal of Morphological Sciences, [S.l.], v. 6, n. 3, p. 78-84, dec. 2023. ISSN 2545-4706. Available at: <https://jms.mk/jms/article/view/vol6no3-11>. Date accessed: 22 oct. 2024.
Citation Formats
Issue
Vol 6 No 3 (2023): JMS
Section
Articles